Page 7 - Replimune Group News Today

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) insider Pamela Esposito sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, July 10th. The shares were sold at an average price of $21.58, for a total transaction of $431,600.00. Following the completion of the transaction, the insider now directly owns 263,436 […]

Collectively referred to as the "Transaction"). The Transaction constituted a reverse takeover of the Company by FTP under applicable securities laws. FTP became a...

Replimune Group, Inc. (NASDAQ:REPL – Get Rating)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $23.48, but opened at $24.60. Replimune Group shares last traded at $24.39, with a volume of 44,521 shares. Wall Street Analysts Forecast Growth A number of research analysts have weighed in […]

Replimune Group (NASDAQ:REPL – Get Rating) had its target price upped by HC Wainwright from $50.00 to $51.00 in a research report sent to investors on Monday morning, The Fly reports. HC Wainwright also issued estimates for Replimune Group’s Q1 2024 earnings at ($0.80) EPS, Q2 2024 earnings at ($0.84) EPS, Q3 2024 earnings at […]

Replimune Group (NASDAQ:REPL – Get Rating) had its price target raised by HC Wainwright from $50.00 to $51.00 in a research report released on Monday, The Fly reports. HC Wainwright also issued estimates for Replimune Group’s Q1 2024 earnings at ($0.80) EPS, Q2 2024 earnings at ($0.84) EPS, Q3 2024 earnings at ($0.88) EPS, Q4 […]

Replimune Group, Inc. announced the appointment of Veleka R. Peeples-Dyer to the Companys Board of Directors effective June 1, 2023. Ms. Peeples-Dyer has served as a strategic enterprise leader at... | June 6, 2023

Responding patient images from the 75 patient snapshot in anti-PD1 failed melanoma Injected lesions ... | June 3, 2023

01.06.2023 - WOBURN, Mass., June 01, 2023 (GLOBE NEWSWIRE) - Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members ...

Replimune Group, Inc. (NASDAQ:REPL – Get Rating) – Wedbush cut their FY2024 earnings per share estimates for shares of Replimune Group in a research note issued to investors on Monday, May 22nd. Wedbush analyst R. Driscoll now expects that the company will post earnings of ($3.95) per share for the year, down from their previous […]

Replimune Group, Inc. (NASDAQ:REPL – Get Rating) has received an average rating of “Buy” from the six research firms that are currently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued ratings on the stock in the […]